Description
Methylisoindigotin is an indirubin derivative that displays anti-inflammatory, anti-angiogenic, and anticancer chemotherapeutic activities. In vitro, methylisoindigotin inhibits growth and proliferation of various leukemia cell lines. In LPS-stimulated macrophages and keratinocytes, methylisoindigotin decreases production of NO and pro-inflammatory cytokines. This compound also induces apoptosis and inhibits tumor growth in animal models of colon adenocarcinoma. In other models, methylisoindigotin decreases GSK expression and downregulates Wnt activity. Additionally, methylisoindigotin decreases production of VEGF and suppresses tube formation in vitro.